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Abstract Washed intact human platelets were prelabelled with 
[3Hlarachidonic acid ([3I-IIAA) and stimulated with thrombin or 
with AIF4, a known unspecific activator of G-proteins. Both 
stimuli induced the liberation of [3H]AA, the release of [3- 
thromboglobulin ([3-TG) and platelet aggregation. PMA did not 
induce liberation of [3H]AA although it induced [~-TG release and 
aggregation; preincnhation with PMA did not modify signifi- 
cantly the amounts of [3H]AA and ~-TG released by thrombin or 
AIF 4. Different inhibitors of PKC (staurosporine, H-7 and 
calphostin C) increased the release of [3H]AA and inhibited [~-TG 
release and aggregation induced by AIF~- but they had no effect 
when platelets were stimulated with thrombin (0.5 U/ml). 
Calphostin C was able to release [3HIAA by itself without 
inducing aggregation or [3-TG release. Okadaic acid (a serine/ 
threonine phosphoprotein phosphatase inhibitor) greatly inhibited 
the release of [ff-IIAA, ~-TG and aggregation in AIF 4-stimulated 
platelets. These results indicate the presence of a G-protein 
mediated mechanism for the activation of a platelet phospho- 
lipase A2 which is negatively affected by a protein kinase, 
sensible to putative inhibitors of protein kinase C, and it is 
activated by a protein phosphatase, sensible to okadaic acid. 
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1. Introduction 
Type II phospholipase A2 (sPLA2) and type IV phospho- 
lipase A2 (cPLA2) have been detected and characterized in hu- 
man platelets. The former enzyme is released from stimulated 
platelets and it is identical to the PLAz present in rheu- 
mathoid synovial fluid [1,2]. Thus, this enzyme is supposed 
to play a role in extracellular fluids after its release from 
secretory granules where it is stored [3]. Whether sPLA2 con- 
tributes to the liberation of arachidonic acid (AA) in stimu- 
lated platelets is still matter of debate. On the other hand, the 
involvement of cPLA2 in the receptor-coupled release of AA 
has been well documented in platelets and in other cell types 
[4-6]. This enzyme has a cytosolic localization, it is highly 
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specific for arachidonoyl residues [4] and it requires ubmicro- 
molar concentration of Ca 2+ and phosphorylation for full 
activation [5]. Since the activation of cPLA2 is of primary 
importance for the generation of bioactive lipid messengers, 
the elucidation of the mechanisms that regulate the activity of 
this enzyme is a key issue for understanding some aspects of 
signal transduction i platelets. 
We have previously compared the effects of an unspecific 
and direct activator of G-proteins, fluoroaluminate (A1F4), 
with those of thrombin on PLA2 activation as well as aggre- 
gation and release of granule contents in intact human plate- 
lets. We have demonstrated that PLA2 activation and the 
release of 13-TG can be induced directly by a G-protein de- 
pendent mechanism, which does not require a previous acti- 
vation of phospholipase C (PLC) [7], differently from what 
happens when thrombin is the stimulus. 
The stimulation of human platelets with thrombin activates 
various protein kinases [8] and cPLA2 is supposed to be the 
substrate of one of them, at least. Mitogen-activated protein 
kinases (MAPK) have been proposed as the enzymes involved 
in cPLA2 phosphorylation following the activation of MAPK 
itself by a tyrosine kinase in thrombin-stimulated platelets [9]. 
However, the involvement of proline-directed kinases, other 
than MAPK, in the activation of platelet cPLAz cannot be 
ruled out [10]. 
In other cell types, PKC-dependent and PKC-independent 
mechanisms for the activation of MAPK and consequently of
cPLA2 have been proposed [11]. 
In platelets, the role of PKC in G-protein mediated activa- 
tion of PLA2 is not well defined. In saponine permeabilized 
rabbit platelets, phorbol 12-myristate 13-acetate (PMA) po- 
tentiates the release of AA induced by non-hydrolysable ana- 
logs of GTP or by Ca 2+ addition [12]. In intact human plate- 
lets, PMA potentiates Ca2+-ionophore induced AA release 
[13] whereas it inhibits the formation of thromboxane B2 
(TxB2) caused by A1F 4 addition [14]. 
AIF 4 induces platelet activation by mechanisms not fully 
elucidated. This compound (10 mM or less) produces diacyl- 
glycerol and TxB2, without activating PLC, and increases 
PKC activity without an apparent increase of intracellular 
Ca 2+ [15]. At higher concentrations (20 mM or more), A1F 4 
activates PLC and liberates TxB2 being the two events inde- 
pendent [7,14]. 
In order to focus upon the role of PKC on the release of 
AA by a G-protein mediated activation of PLA2, we have 
assessed the effects of PMA (PKC activator) or known in- 
hibitors of protein kinases (staurosporine, H-7 and calphostin 
C) or of protein phosphatases (okadaic acid) on the produc- 
tion of radioactive AA in human intact platelets, prelabelled 
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with [3H]AA, and stimulated with A1F~-, a direct activator of 
G-protein. The results of these experiments have been com- 
pared to those obtained by stimulating platelets with throm- 
bin through a receptor-mediated mechanism. In both cases, 
functional parameters as platelet aggregation and secretion 
have been also determined. 
2. Materials and methods 
2.1. Materials 
[5,6,8,9,11,12,14,15-3H]Arachidonic acid ([3H]AA; 191-220 Ci/ 
mmol) was purchased from NEN Research Products (Boston, MA, 
USA). Prostacyclin (PGI2), bovine serum albumin (BSA fraction V), 
and apyrase were from Sigma Chemicals (USA). Bovine thrombin 
(Topostasin) was from Roche (Basel, Switzerland). Staurosporine, 
H-7 (1-(5-isoquinolinylsulfonyl)-2-methylpiperazine), calphostin C 
and okadaic acid were purchased from Calbiochem-Novabiochem 
Int. (San Diego, CA, USA). Silica gel 60A plates (Whatman Int. 
Ltd., Maidstone, UK) were used for thin-layer chromatography. 
2.2. Preparation of platelets labelled with [3H]arachidonie acid 
Washed labelled platelets (WLP) were prepared as previously re- 
ported [7]. Briefly, blood (50-80 ml) was drawn from healthy volun- 
teers in citrate-dextrose as anticoagulant (1:6 volumes of blood) and 
washed platelets were prepared in the presence of 0.2 ~tM PGI2, 50 U/ 
ml heparin and 0.01 mg/ml apyrase and incubated with [3H]AA (1 
~Ci/ml of platelet suspension) at 37°C for 1 h. The unincorporated 
precursor was removed by further washings. Finally, WLP were re- 
suspended at250,000/Ixl in a convenient volume of Tyrode-BSA buffer 
(pH 7.4) without Ca 2+ and Mg 2+. 
2.3. Stimulation of washed labelled platelets 
0.5 ml WLP suspension was stimulated and with thrombin 0.5 U/ml 
for 3 rain or with 21 mM A1F~- (NaF and A1C13 solution in a 5000:1 
molar ratio) for 20 min under continuous stirring at 1,100 rpm [7]. 
When indicated, WLP were preincubated with PMA (100 nM for 
5 rain) or staurosporine (200 nM for 4 min) or H-7 (200 p.M for 
4 min) or calphostin C (2 IzM for 4 min) or okadaic acid (1 I.tM for 
4 min or for 10 min) before stimulation with A1F~- or with thrombin. 
Platelet aggregation was monitored by photometric method (Aggre- 
corder, Menarini, Milan, Italy). At the end of the stimulation period, 
0.1 ml platelet suspension were taken for ~-TG determination a d the 
remaining amount for lipid analysis. 
2.4. Extraction and analysis of lipids 
Lipids were extracted and AA and phosphatidic acid (PA) were 
isolated by TLC as previously described [7]. The corresponding areas 
were scraped off and their radioactivity determined by liquid scintilla- 
tion counting (Emulsifier-safe, Packard Instrument Co., IL) and 
quenching corrected by external standardization. 
2.5, Determination of B-thromboglobulin 
0.1 ml platelet suspensions were immediately centrifuged at 
12,000 ×g for 2 min and the supernatant stored at -80°C for subse- 
quent assay of ~-TG which was performed by ELISA (Boehringer, 
Mannheim, Germany) [16]. 
2.6. Statistical analysis 
Unless differently indicated, statistical nalysis of the data was car- 
ried out by ANOVA followed by multiple comparison (Sheffe's test). 
3. Results 
Human platelets, prelabelled with [3H]AA and stimulated 
with thrombin or fluoroaluminate, released this fatty acid 
from membrane phospholipids, liberated I]-TG from -granules 
and aggregated (Table 1). Concentrations of agonists and 
times of stimulation were chosen to give comparable biochem- 
ical and functional effects [7]. The exposure of platelets to 100 
nM PMA for 5 min did not increase the radioactivity of AA 
although induced I]-TG release (near 40% of total content) 
and platelet aggregation. Since PMA activates PKC, this re- 
sult indicates that, in intact platelets, this enzyme does not 
induce direct activation of PLA2 but it participates to secre- 
tion and aggregation. The preincubation of platelets with 
PMA (100 nM) did not modify significantly the release of 
[3H]AA from thrombin- or A1F4-stimulated platelets (Table 
1). 
The preincubation of WLP with staurosporine (200 nM) or 
with H-7 (200 IxM) increased the release of labelled AA by 70- 
80%, reduced the release of [~-TG by more than 50% and 
blocked completely the aggregation when platelets were stimu- 
lated with A1F 4 (Table 2). A rather different pattern of effects 
were observed instead when platelets were stimulated with 0.5 
U/ml thrombin. In fact, the treatment with staurosporine or 
H-7 had virtually no effect on the radioactivity of free AA or 
on the release of ~-TG or platelet aggregation (Table 2). 
When platelets were preincubated with calphostin C (2 p,M) 
for 4 min before stimulation with A1F~-, aggregation was 
completely blocked, [~-TG release was inhibited by nearly 
60% (total content of ~-TG = 9222 + 643 (n = 6) ng/ml; A1F~- 
(21 mM) = 3327 + 1696 (n = 17); calphostin C (2 ~tM) + A1F~- 
(21 mM)=1427+316 (n=4)) but the liberation of [3H]AA 
was increased by nearly 100% (Fig. 1). Under identical con- 
ditions, the release of [aH]AA tended to increase in thrombin- 
stimulated WLP preincubated with calphostin (Fig. 1) 
whereas the release of [~-TG and platelet aggregation were 
slightly reduced (data not shown). Calphostin C induced by 
itself an increase of the radioactivity associated with free AA 
(Fig. 1) but had no effect on platelet aggregation (data not 
shown). 
Table 1 
The effect of fluoroaluminate, hrombin or PMA on the production of arachidonic acid, on the release of [3-TG and aggregation i intact hu- 
man platelets 
Treatment AA production I~-TG release % of maximal 
(nCi/109 platelets) (ng/ml) aggregation 
Resting 10.1 + 1.5 (22) 381 + 79 (7) 0 
PMA (100 nM) 12.1 + 1.6 (10) 3588 + 646 (9) 55 _+ 5 (9) 
A1F~- 50.7 + 3.4 (22) b 3327 +_ 411 (17) b 51 +_ 3 (8) 
PMA 100 nM+AIF~- 42.1 + 4.2 (16) 3678 + 528 (17) b 52 + 2 (9) 
Thrombin 65.9 +_ 5.6 (18) b 4028 + 396 (16) b 55 + 2 (10) 
PMA 100 nM+ thrombin 56.9 + 8.2 (10) b 4062 + 590 (8) b 55 + 3 (8) 
Washed labelled platelets (WLP) were prepared and [3H]AA, [$-TG release and aggregation were determined as described in section 2. WLP 
were stimulated with AIF~- (21.1 mM NaF + 4.2 IxM AICI3) for 20 min or with 0.5 U/ml thrombin for 3 min. When indicated WLP were 
preincubated with 100 nM PMA for 5 min before stimulation. Data are the means + S.E.M. Total content (Triton X-100 extraction) of 13-TG 
in WLP was 9222 _+ 287 (n = 5) ng/ml. 
bp < 0.05 vs. resting. Number of determinations between brackets. 
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Fig. 1. The effect of calphostin C on the production of arachidonic 
acid in intact human platelet stimulated with ftuoraluminate or
thrombin. Washed labelled platelet (WLP) preparations and [aH]AA 
release determination were performed as described in section 2. 
WLP were stimulated with AIF 4 (21.1 mM NaF+4.2 ~tM AIC13) 
for 20 rain (F) or with 0.5 U/ml thrombin for 3 min (T). When in- 
dicated WLP were preincubated before stimulation with calphostin 
C (2 M) for 4 min (C). Data are the means + S.E.M. from at least 
two experiments in duplicate. R = resting platelets. *P < 0.01 vs. R; 
§P<0.01 vs. C; #P<0.01 vs. F. 
As shown in Table 3, the stimulation of WLP with A1F 4 or 
with thrombin caused nearly 100% increase of phosphatidic 
acid (PA) radioactivity which was not significantly affected by 
the exposure to staurosporine or to H-7. On the other hand, 
calphostin C reduced the increase of the radioactivity of PA 
induced by A1F 4 but had no effect on that induced by throm- 
bin (Table 3). 
Pretreatment of platelets with 1 ~tM okadaic acid for 4 min 
before stimulation with A1F~- induced a marked decrease of 
AA liberation, [3-TG release (Fig. 2) and completely inhibited 
platelet aggregation. The same treatment did not cause signif- 
icant changes of these parameters in thrombin-stimulated 
platelets, whereas they were reduced by 20-30% when prein- 
cubation with okadaic acid was prolonged to 10 min (data not 
shown). 
4. Discussion 
The release of AA from stimulated platelets is attributed 
essentially to the activation of PLA2. It remains to be estab- 
lished whether a single enzyme, likely cPLA2, is the target of 
multiple signals converging to a common mechanism of en- 
zyme activation or if different platelet stimuli activate different 
PLA2s through distinct pathways. 
In the present study, we have stimulated human platelets by 
a direct and unspecific G-protein activator (A1F~-) which in- 
duces platelets to aggregate, to release 13-TG from ct-granules 
and to produce free AA by the hydrolysis of membrane phos- 
pholipids, through a mechanism which differs from that in- 
itiated by thrombin, at least in part [7]. 
We have assessed the involvement of PKC in these phenom- 
ena by using an activator (PMA) or several inhibitors (stauro- 
sporine, H-7 or calphostin C) of the enzyme. Other Authors 
have shown that, in permeabilized rabbit platelets, PMA po- 
tentiates AA release induced by GTP-S or AIF~- in the pres- 
ence of 100 ~tM external Ca 2+ concentration while stauro- 
sporine had an inhibitory effect [12]. On the contrary, our 
results have shown that the exposure of intact platelets, resus- 
pendended in a medium without added Ca 2+, to PMA did not 
increase the release of AA induced by AIF 4 or with thrombin. 
The discrepancy between our and previous studies cannot be 
attributed to a failure of PMA to activate PKC since ~-TG 
release from a-granules, a PKC-mediated process, took place 
(Table 1), and it was reduced by staurosporine (data not 
shown). Thus, it can be suggested that the potentiation by 
PKC of the G-protein mediated activation of PLA~, reported 
with rabbit permeabilized platelets [12], requires a relative 
high Ca 2+ concentration which might be provided by an in- 
flux from the external medium. This hypothesis is supported 
by the observation that, in human platelets stimulated by 
Ca2+-ionophore, the release of AA is also potentiated by 
PMA and inhibited by staurosporine and H-7 [13]. 
Table 2 
The effect of protein kinase inhibitors on the production of arachidonic acid, on the release of 13-TG and on aggregation i intact human plate- 
let stimulated with fluoroaluminate or thrombin 
Treatment AA production ~-TG release Aggregation 
(nCi/109 platelets) (ng/ml) (% of control) 
Resting 10.1+ 1.5 (22) 381 + 79 (17) 0 
Staurosporine 8.2+ 0.7 (5) 475 + 14 (2) 0 (5) 
H-7 6.6+ 1.4 (2) - 0 (2) 
AIF 4 50.7 + 3.4 (22) b 3327 + 411 (17) b 100 
Staurosporine + AIF 4 88.5 + 9.6 (14) a 1528 + 206 (12) a 6.2+ 2.1 (12) 
H-7 + AIF~ 93.8 + 14.7 (6) a 1207 + 208 (6) a 19.2+ 11.8 (6) 
Thrombin 113.8 + 6.4(5) b 3042 + 222 (8) b 100 
Staurosporine + Thrombin 98.9 + 8.3 (6) 3928 + 282 (8) 100.9+ 3.3 (10) 
H-7 + Thrombin 91.0 + 4.7 (6) 3019 + 584 (6) 98+ 4 (4) 
WLP were stimulated with A1F 4 (21.1 mM NaF+4.2 p.M AICI3) for 20 min or with 0.5 U/ml thrombin for 3 min. When indicated WLP were 
alternatively preincubated before stimulation with staurosporine 200 nM for 4 min or H-7 200 ~tM for 4 rain. Data are the mean _+ S.E.M. with 
number of determinations between brackets. Total content (Triton X-100 extraction) of I3-TG in WLP was 9222 + 287 (n = 5) ng/ml. 
~P< 0.05 vs. AIF~-. 
bp < 0.05 vs. resting. 
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Fig. 2. Effect of okadaic acid on AA liberation, ~-TG release and 
aggregation i intact human platelets. WLP were preincubated with 
1 ~tM okadaic acid for 4 min (OA) and stimulated with AIF~- (21.1 
mM NaF + 4.2 I~M A1C13) for 20 min. Data are the mean + S.E.M. 
from 3 experiments in duplicate. *P<0.0001 and **P<0.05 vs. 
stimulated control (Student's t-test). 
Most interestingly, we have demonstrated that staurospor- 
ine or H-7, unspecific PKC inhibitors, and the more selective 
calphostin C, increased the amount of AA released by A1F 4 
while abolished the release of ~-TG (Table 2). These results 
indicate that, in intact human platelets, there is a G-protein 
mediated mechanism for the activation of a PLA2 which is 
downregulated by PKC or another protein kinase(s) sensible 
Table 3 
The effect of fluoroaluminate, thrombin and of three different pro- 
tein kinase inhibitors on the formation of radioactive phosphatidic 
acid (PA) 
Treatment PA radioactivity 
(nCi/109 platelets) 
Resting 
AIF 4 
Staurosporine (200 nM)+ A1F 4 
H-7 (200 ~tM) + A1F 4 
Calphostin C (2 I.tM)+ A1F~- 
Thrombin 
Staurosporine (200 nM) + Thrombin 
H-7 (200 I.tM) + Thrombin 
Calphostin C (2 IxM)+ Thrombin 
6.18+3.17 (20) 
18.6+7.87 (21) ~ 
14.8+_5.7 (12) 
12.7+- 1.5 (4) 
8.7 + 2.0 (5) b 
15.7+3.2 (15) a 
14.1 _+ 3.2 (8) 
11.7 + 3.4 (6) 
11.6+6.8 (4) 
WLP were stimulated with AIF 4 (21.1 mM NaF+4.2 IxM AICI3) 
for 20 min or with 0.5 U/ml thrombin for 3 min. Data are the 
mean + S.E.M. 
~P< 0.05 vs. resting. 
6P < 0.05 vs. AIF~-. 
to staurosporine, H-7 or calphostin C. Thus, this enzyme must 
be different from that described in previous tudies [12,13]. 
A1F4-stimulated PLA2 is likely to be Ca2+-independent [17] 
or to require low Ca 2+ concentration. In fact, the stimulation 
of intact human platelets, resuspended in a Ca 2+-free medium, 
increases intracellular [Ca 2+] up to 500 nM [18], a concentra- 
tion which might be sufficient o activate cPLA2. If cPLA2 is 
the enzyme which is activated in our experimental conditions, 
we can exclude that staurosporine, H-7 and calphostin C act 
on MAPK or other proline-directed kinases, which have 
cPLA2 as substrate, because the latter enzyme is more active 
when phosphorylated [10,11]. 
Differently from what observed with A1F4, PKC inhibitors 
have no effect on the formation of labelled AA, 13-TG release 
and aggregation induced by 0.5 U/ml thrombin (Table 2). 
This discrepancy might be due to differences in the signal 
transduction pathways leading to PLA2 activation in recep- 
tor-stimulated versus A1F 4 (G-protein)-activated platelets. Al- 
ternatively, it is possible that the two stimuli lead to the acti- 
vation of different enzymes. 
Calphostin C, differently from staurosporine and H-7, in- 
duced the direct release of [3H]AA. A similar finding has been 
reported in human neutrophils where this compound induced 
a dose-dependent release of AA [19]. In addition, calphostin C
inhibits the labelling of PA in A1F~--stimulated platelets (Ta- 
ble 3). These effects are not probably related to the inhibition 
of PKC because staurosporine or H-7 were not able to induce 
a direct AA release or to reduce PA formation, These obser- 
vations further encourage caution in considering calphostin C
simply a PKC-inhibitor. 
We have found that the treatment of intact platelets with 
okadaic acid, a specific inhibitor of protein phosphatases 1 
and 2A, causes a marked reduction of AA liberation, [3-TG 
release and prevents the aggregation i A1F~--stimulated plate- 
lets and, to a lesser extent, in thrombin-stimulated platelets. 
Although several studies have been reported on the effect of 
inhibitors of protein phosphatases on platelet release and ag- 
gregation [20,21], so far no information is available concern- 
ing AA release in intact cells. Okadaic acid inhibits thrombin 
induced platelet activation through a potentiation of the in- 
hibition of phospholipase C produced by PKA and PKC [22]. 
Since the release of AA in A1F~- -stimulated platelets does not 
depend on PLC activation [7], in our experiments he effects 
of okadaic acid must be produced by another mechanism. 
In conclusion, we suggest he existence in intact human 
platelets of a G-protein mediated mechanism for the activa- 
tion of a PLA2 which is regulated by phosphorylation~lepho- 
sphorylation reactions where a protein kinase(s), sensible to 
PKC inhibitors, should exert a negative modulation of PLA2 
activity while a protein phosphatase(s), sensible to okadaic 
acid, should have the opposite effect. The nature of these 
enzymes and their location in the cascade of events leading 
to PLA2 activation remains to be established. 
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